Atomoxetine and Huntington's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Huntington DiseaseChorea
Interventions
DRUG

atomoxetine

This study utilizes a crossover design. Accordingly, half of the participants receive 40 milligram twice a day atomoxetine at arm one while the remaining half receive this intervention at arm two.

DRUG

Matching Placebo

This study utilizes a crossover design. Accordingly, half of the participants receive twice a day matching placebo at arm one while the remaining half receive this intervention at arm two.

Trial Locations (1)

52242

The University of Iowa, Iowa City

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Iowa

OTHER

NCT00368849 - Atomoxetine and Huntington's Disease | Biotech Hunter | Biotech Hunter